These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 19321593

  • 21. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
    Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M.
    Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
    [Abstract] [Full Text] [Related]

  • 22. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
    Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK.
    Cancer Res; 2008 Jun 15; 68(12):4511-7. PubMed ID: 18559494
    [Abstract] [Full Text] [Related]

  • 23. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M, Udagawa Y.
    Oncol Rep; 2011 Apr 15; 25(4):1131-8. PubMed ID: 21249319
    [Abstract] [Full Text] [Related]

  • 24. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, Glud E, Jacobs IJ, Høgdall CK.
    Cancer; 2004 Jun 01; 100(11):2387-95. PubMed ID: 15160342
    [Abstract] [Full Text] [Related]

  • 25. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM.
    Clin Cancer Res; 2003 Nov 01; 9(14):5318-24. PubMed ID: 14614016
    [Abstract] [Full Text] [Related]

  • 26. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC, Gynecologic Oncology Group.
    Cancer; 2008 May 15; 112(10):2202-10. PubMed ID: 18348296
    [Abstract] [Full Text] [Related]

  • 27. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H.
    Cancer Invest; 2008 Mar 15; 26(2):185-92. PubMed ID: 18259951
    [Abstract] [Full Text] [Related]

  • 28. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr 15; 42(4):227-32. PubMed ID: 17631760
    [Abstract] [Full Text] [Related]

  • 29. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group.
    J Clin Oncol; 2008 Jan 01; 26(1):83-9. PubMed ID: 18025437
    [Abstract] [Full Text] [Related]

  • 30. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK, Chao TK, Yu CP, Yu MH, Jin JS.
    APMIS; 2009 Mar 01; 117(3):162-75. PubMed ID: 19245589
    [Abstract] [Full Text] [Related]

  • 31. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
    Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Nassar H, Ali-Fehmi R.
    Gynecol Oncol; 2006 Jun 01; 101(3):385-9. PubMed ID: 16443262
    [Abstract] [Full Text] [Related]

  • 32. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.
    Gynecol Oncol; 2006 Dec 01; 103(3):831-40. PubMed ID: 16919315
    [Abstract] [Full Text] [Related]

  • 33. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation.
    Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, Hölscher AH, Mönig SP.
    Oncol Rep; 2008 Jun 01; 19(6):1477-83. PubMed ID: 18497953
    [Abstract] [Full Text] [Related]

  • 34. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer.
    Yin M, Li C, Li X, Lou G, Miao B, Liu X, Meng F, Zhang H, Chen X, Sun M, Ling Q, Zhou R.
    J Surg Oncol; 2011 Jul 01; 104(1):29-36. PubMed ID: 21416470
    [Abstract] [Full Text] [Related]

  • 35. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications.
    Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, Thymara I, Scliri M, Bousboukea K, Michalopoulos NV, Apostolikas N, Konstantinidou A, Tzivras M, Patsouris E.
    Histopathology; 2007 Aug 01; 51(2):150-6. PubMed ID: 17559541
    [Abstract] [Full Text] [Related]

  • 36. Relations between immunologically different p53 forms, p21(WAF1) and PCNA expression in ovarian carcinomas.
    Harlozinska A, Bar JK, Montenarh M, Kartarius S.
    Oncol Rep; 2002 Aug 01; 9(6):1173-9. PubMed ID: 12375014
    [Abstract] [Full Text] [Related]

  • 37. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S.
    Clin Cancer Res; 2008 Mar 15; 14(6):1726-33. PubMed ID: 18347173
    [Abstract] [Full Text] [Related]

  • 38. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
    Mayr D, Pannekamp U, Baretton GB, Gropp M, Meier W, Flens MJ, Scheper R, Diebold J.
    Pathol Res Pract; 2000 Mar 15; 196(7):469-75. PubMed ID: 10926324
    [Abstract] [Full Text] [Related]

  • 39. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T, Alshaikh G, Hopkins L, Faught W, Fung MF.
    Ann Surg Oncol; 2006 Dec 15; 13(12):1711-6. PubMed ID: 17009146
    [Abstract] [Full Text] [Related]

  • 40. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I, Seidal T.
    Int J Gynecol Cancer; 2011 Aug 15; 21(6):1024-31. PubMed ID: 21792012
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.